433.07
-20.67 (-4.56%)
| Previous Close | 453.74 |
| Open | 450.95 |
| Volume | 1,915,411 |
| Avg. Volume (3M) | 1,440,454 |
| Market Cap | 110,014,586,880 |
| Price / Earnings (TTM) | 28.25 |
| Price / Earnings (Forward) | 23.81 |
| Price / Sales | 9.76 |
| Price / Book | 6.18 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Profit Margin | -8.91% |
| Operating Margin (TTM) | 37.22% |
| Diluted EPS (TTM) | -3.80 |
| Quarterly Revenue Growth (YOY) | 3.00% |
| Quarterly Earnings Growth (YOY) | -41.20% |
| Total Debt/Equity (MRQ) | 10.00% |
| Current Ratio (MRQ) | 2.65 |
| Operating Cash Flow (TTM) | -980.30 M |
| Levered Free Cash Flow (TTM) | 2.63 B |
| Return on Assets (TTM) | 11.77% |
| Return on Equity (TTM) | -5.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vertex Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 97.64% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 641.00 (HC Wainwright & Co., 48.01%) | Buy |
| Median | 558.00 (28.85%) | |
| Low | 441.00 (Canaccord Genuity, 1.83%) | Hold |
| Average | 557.40 (28.71%) | |
| Total | 12 Buy, 3 Hold | |
| Avg. Price @ Call | 488.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 11 Mar 2026 | 525.00 (21.23%) | Buy | 492.38 |
| B of A Securities | 10 Mar 2026 | 598.00 (38.08%) | Buy | 499.17 |
| Citigroup | 10 Mar 2026 | 585.00 (35.08%) | Buy | 499.17 |
| HC Wainwright & Co. | 10 Mar 2026 | 641.00 (48.01%) | Buy | 499.17 |
| 17 Feb 2026 | 591.00 (36.47%) | Buy | 477.32 | |
| Jefferies | 10 Mar 2026 | 580.00 (33.93%) | Buy | 499.17 |
| Morgan Stanley | 10 Mar 2026 | 596.00 (37.62%) | Buy | 499.17 |
| Oppenheimer | 10 Mar 2026 | 600.00 (38.55%) | Buy | 499.17 |
| 13 Feb 2026 | 540.00 (24.69%) | Buy | 491.47 | |
| Barclays | 17 Feb 2026 | 607.00 (40.16%) | Buy | 477.32 |
| 28 Jan 2026 | 606.00 (39.93%) | Buy | 477.91 | |
| Canaccord Genuity | 17 Feb 2026 | 441.00 (1.83%) | Hold | 477.32 |
| RBC Capital | 13 Feb 2026 | 541.00 (24.92%) | Buy | 491.47 |
| 22 Jan 2026 | 546.00 (26.08%) | Buy | 467.35 | |
| Scotiabank | 13 Feb 2026 | 558.00 (28.85%) | Hold | 491.47 |
| Stifel | 13 Feb 2026 | 466.00 (7.60%) | Hold | 491.47 |
| UBS | 26 Jan 2026 | 545.00 (25.85%) | Buy | 476.84 |
| 07 Jan 2026 | 535.00 (23.54%) | Buy | 484.15 | |
| Evercore ISI Group | 23 Jan 2026 | 530.00 (22.38%) | Buy | 468.41 |
| Wolfe Research | 06 Jan 2026 | 548.00 (26.54%) | Buy | 468.38 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager |
| 29 Jan 2026 | Announcement | Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs |
| 26 Jan 2026 | Announcement | Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets |
| 20 Jan 2026 | Announcement | Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th |
| 11 Jan 2026 | Announcement | Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings |
| 02 Jan 2026 | Announcement | Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |